Jennifer Jarrett
CIK: 0001671311
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (21 total)
- Sep 25, 2026DMRA
Damora Therapeutics, Inc.
Purchase(P)Direct12.5K shares at avg. $20.23$253K - Jun 17, 2026ZURA
Zura Bio Ltd
Award(A)DirectShare Option (Right to Buy)
51K shares- - Jun 12, 2026SGMT
Sagimet Biosciences Inc.
Award(A)DirectStock Option (Right to Buy)
39.6K shares- - Mar 30, 2026DMRA
Damora Therapeutics, Inc.
Award(A)Direct500K shares- - Feb 4, 2026SNDX
Syndax Pharmaceuticals Inc
Award(A)Direct24K shares- - Jan 23, 2026RCUS
Arcus Biosciences, Inc.
Award(A)Direct31K shares- - Dec 17, 2025RCUS
Arcus Biosciences, Inc.
Sale(S)Direct10K shares at avg. $22.16$221K - Dec 16, 2025RCUS
Arcus Biosciences, Inc.
Sale(S)Direct11.2K shares at avg. $21.88$246K - Nov 7, 2025RCUS
Arcus Biosciences, Inc.
Sale(S)Direct50.3K shares at avg. $18.97$954K - Nov 7, 2025RCUS
Arcus Biosciences, Inc.
Exercise(M)Direct50.3K shares at avg. $1.23$62K - Oct 8, 2025RCUS
Arcus Biosciences, Inc.
Sale(S)Direct37.8K shares at avg. $15.05$569K - Oct 8, 2025RCUS
Arcus Biosciences, Inc.
Exercise(M)Direct37.8K shares at avg. $1.23$46K - Oct 6, 2025RCUS
Arcus Biosciences, Inc.
Exercise(M)Direct12.5K shares at avg. $1.23$15K - Oct 6, 2025RCUS
Arcus Biosciences, Inc.
Sale(S)Direct12.5K shares at avg. $14.54$182K - Jun 9, 2025SGMT
Sagimet Biosciences Inc.
Award(A)DirectStock Option (Right to Buy)
27.3K shares- - May 21, 2025ZURA
Zura Bio Ltd
Award(A)DirectShare Option (Right to Buy)
51K shares- - Feb 5, 2025SNDX
Syndax Pharmaceuticals Inc
Award(A)Direct25K shares- - Jan 23, 2025RCUS
Arcus Biosciences, Inc.
Award(A)Direct50K shares- - Dec 15, 2024RCUS
Arcus Biosciences, Inc.
Tax Payment(F)Direct27.5K shares at avg. $16.08$442K - Dec 9, 2024ZURA
Zura Bio Ltd
Award(A)DirectShare Option (Right to Buy)
117K shares- - Sep 15, 2024RCUS
Arcus Biosciences, Inc.
Tax Payment(F)Direct12.7K shares at avg. $17.95$227K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 25, 2026 |  DMRA Damora Therapeutics, Inc. | Purchase(P) | 12,500 | $20.23 | $252,875 | Direct |
| Jun 17, 2026 |  ZURA Zura Bio Ltd | Award(A) Share Option (Right to Buy) | 51,000 | - | - | Direct |
| Jun 12, 2026 |  SGMT Sagimet Biosciences Inc. | Award(A) Stock Option (Right to Buy) | 39,567 | - | - | Direct |
| Mar 30, 2026 | DMRA Damora Therapeutics, Inc. | Award(A) | 500,000 | - | $0 | Direct |
| Feb 4, 2026 |  SNDX Syndax Pharmaceuticals Inc | Award(A) | 24,000 | - | $0 | Direct |
| Jan 23, 2026 |  RCUS Arcus Biosciences, Inc. | Award(A) | 31,000 | - | $0 | Direct |
| Dec 17, 2025 | RCUS Arcus Biosciences, Inc. | Sale(S) | 9,983 | $22.16 | $221,218 | Direct |
| Dec 16, 2025 | RCUS Arcus Biosciences, Inc. | Sale(S) | 11,225 | $21.88 | $245,651 | Direct |
| Nov 7, 2025 | RCUS Arcus Biosciences, Inc. | Sale(S) | 50,291 | $18.97 | $954,066 | Direct |
| Nov 7, 2025 | RCUS Arcus Biosciences, Inc. | Exercise(M) | 50,291 | $1.23 | $61,737 | Direct |
| Oct 8, 2025 | RCUS Arcus Biosciences, Inc. | Sale(S) | 37,792 | $15.05 | $568,611 | Direct |
| Oct 8, 2025 | RCUS Arcus Biosciences, Inc. | Exercise(M) | 37,792 | $1.23 | $46,393 | Direct |
| Oct 6, 2025 | RCUS Arcus Biosciences, Inc. | Exercise(M) | 12,500 | $1.23 | $15,345 | Direct |
| Oct 6, 2025 | RCUS Arcus Biosciences, Inc. | Sale(S) | 12,500 | $14.54 | $181,801 | Direct |
| Jun 9, 2025 | SGMT Sagimet Biosciences Inc. | Award(A) Stock Option (Right to Buy) | 27,268 | - | - | Direct |
| May 21, 2025 | ZURA Zura Bio Ltd | Award(A) Share Option (Right to Buy) | 51,000 | - | - | Direct |
| Feb 5, 2025 | SNDX Syndax Pharmaceuticals Inc | Award(A) | 25,000 | - | - | Direct |
| Jan 23, 2025 | RCUS Arcus Biosciences, Inc. | Award(A) | 50,000 | - | $0 | Direct |
| Dec 15, 2024 | RCUS Arcus Biosciences, Inc. | Tax Payment(F) | 27,501 | $16.08 | $442,216 | Direct |
| Dec 9, 2024 | ZURA Zura Bio Ltd | Award(A) Share Option (Right to Buy) | 117,000 | - | - | Direct |
| Sep 15, 2024 | RCUS Arcus Biosciences, Inc. | Tax Payment(F) | 12,670 | $17.95 | $227,427 | Direct |
1-21 of 21 transactions
About Jarrett Jennifer
Jarrett Jennifer (SEC CIK 0001671311) files insider reports with the SEC as Director, President and CEO of Damora Therapeutics, Inc. (DMRA), Director of Zura Bio Ltd (ZURA) and Director of Sagimet Biosciences Inc. (SGMT). Signal8 also holds filings tied to 2 other companies.
Signal8 holds 17 ownership filings by Jarrett Jennifer (1 Form 3, 16 Form 4), filed between Sep 17, 2024 and Sep 28, 2026. Those filings report 21 transactions, from Sep 15, 2024 to Sep 25, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Jarrett Jennifer's filings is in WALTHAM, MA.
Recent filings by Jarrett Jennifer
- Sep 25, 2026: Open-market purchase of DMRA shares (Form 4, code P).
- Jun 17, 2026: Grant or award of ZURA derivative securities (Form 4, code A).
- Jun 12, 2026: Grant or award of SGMT derivative securities (Form 4, code A).
- Mar 30, 2026: Grant or award of DMRA shares (Form 4, code A).
- Feb 4, 2026: Grant or award of SNDX shares (Form 4, code A).
Other insiders filing for Damora Therapeutics, Inc. (DMRA)
- Cheng Andrew, Director
- Winslow Garrett, General Counsel
- Burkavage Brian, SVP, Finance
- Turtle Cameron, Director
- Landsittel Michael, Director
- Fairmount Funds Management LLC, Director